TY - JOUR
T1 - Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma
AU - Lee, Xiaolong
AU - Gao, Ming
AU - Ji, Yifeng
AU - Yu, Yang
AU - Feng, Ying
AU - Li, Yigong
AU - Zhang, Yan
AU - Cheng, Wenyuan
AU - Zhao, Wenchuan
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/2
Y1 - 2009/2
N2 - Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF V600E mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAFV600E mutational status of them was identified. BRAFV600E mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAFV600E mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAFV600E mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAFV600E mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF V600E mutation may be a marker of high aggressiveness in PTMCs.
AB - Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF V600E mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAFV600E mutational status of them was identified. BRAFV600E mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAFV600E mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAFV600E mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAFV600E mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF V600E mutation may be a marker of high aggressiveness in PTMCs.
UR - http://www.scopus.com/inward/record.url?scp=59449090715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59449090715&partnerID=8YFLogxK
U2 - 10.1245/s10434-008-0233-3
DO - 10.1245/s10434-008-0233-3
M3 - Article
C2 - 19034577
AN - SCOPUS:59449090715
SN - 1068-9265
VL - 16
SP - 240
EP - 245
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 2
ER -